Opaleye Management as of Sept. 30, 2023
Portfolio Holdings for Opaleye Management
Opaleye Management holds 40 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Harrow Health (HROW) | 17.9 | $55M | 3.8M | 14.37 | |
Acelyrin (SLRN) | 13.8 | $42M | 4.1M | 10.17 | |
Ocular Therapeutix (OCUL) | 6.7 | $20M | 6.5M | 3.14 | |
Tg Therapeutics (TGTX) | 5.2 | $16M | 1.9M | 8.36 | |
Rhythm Pharmaceuticals (RYTM) | 4.9 | $15M | 653k | 22.93 | |
Catalyst Pharmaceutical Partners (CPRX) | 4.6 | $14M | 1.2M | 11.69 | |
Keros Therapeutics (KROS) | 3.8 | $12M | 360k | 31.88 | |
Biohaven (BHVN) | 3.7 | $11M | 439k | 26.01 | |
Crinetics Pharmaceuticals In (CRNX) | 3.6 | $11M | 370k | 29.74 | |
Eton Pharmaceuticals (ETON) | 3.3 | $10M | 2.4M | 4.17 | |
Ideaya Biosciences (IDYA) | 2.8 | $8.4M | 312k | 26.98 | |
Morphosys Sponsored Ads (MOR) | 2.7 | $8.1M | 1.2M | 6.72 | |
Tela Bio (TELA) | 2.0 | $6.0M | 750k | 8.00 | |
Edgewise Therapeutics (EWTX) | 1.6 | $5.0M | 875k | 5.73 | |
Kalvista Pharmaceuticals (KALV) | 1.6 | $4.8M | 500k | 9.63 | |
Marinus Pharmaceuticals Com New (MRNS) | 1.5 | $4.7M | 584k | 8.05 | |
Vaxcyte (PCVX) | 1.5 | $4.6M | 90k | 50.98 | |
Protara Therapeutics Com Stk (TARA) | 1.5 | $4.5M | 2.7M | 1.67 | |
Urogen Pharma (URGN) | 1.5 | $4.5M | 320k | 14.01 | |
Geron Corporation (GERN) | 1.3 | $4.1M | 1.9M | 2.12 | |
Gossamer Bio (GOSS) | 1.3 | $4.0M | 4.8M | 0.83 | |
4d Molecular Therapeutics In (FDMT) | 1.3 | $3.9M | 309k | 12.73 | |
Xoma Corp Del Com New (XOMA) | 1.3 | $3.9M | 275k | 14.09 | |
Trevi Therapeutics (TRVI) | 1.2 | $3.7M | 1.7M | 2.18 | |
Liquidia Corporation Com New (LQDA) | 1.2 | $3.6M | 571k | 6.34 | |
Larimar Therapeutics (LRMR) | 1.1 | $3.4M | 849k | 3.95 | |
Nyxoah S A SHS (NYXH) | 1.0 | $3.1M | 442k | 7.05 | |
Gossamer Bio Note 5.000% 6/0 | 1.0 | $3.1M | 8.0M | 0.39 | |
Iovance Biotherapeutics (IOVA) | 0.9 | $2.8M | 610k | 4.55 | |
Applied Therapeutics (APLT) | 0.7 | $2.2M | 893k | 2.49 | |
Igm Biosciences (IGMS) | 0.7 | $2.2M | 261k | 8.35 | |
Codexis (CDXS) | 0.7 | $2.1M | 1.1M | 1.89 | |
Verastem Com New (VSTM) | 0.6 | $1.7M | 211k | 8.13 | |
Precigen (PGEN) | 0.4 | $1.3M | 929k | 1.42 | |
Tracon Pharmaceuticals Com New | 0.3 | $848k | 4.8M | 0.18 | |
Biodesix (BDSX) | 0.2 | $752k | 456k | 1.65 | |
Xeris Pharmaceuticals (XERS) | 0.2 | $725k | 390k | 1.86 | |
Fortress Biotech | 0.2 | $581k | 2.0M | 0.29 | |
Kezar Life Sciences (KZR) | 0.2 | $506k | 425k | 1.19 | |
Relmada Therapeutics (RLMD) | 0.0 | $90k | 30k | 3.00 |